phenox announces the expansion of technology portfolio for AIS with the global launch of the pRESET® 6-50 thrombectomy device.

Andita Paramitha

pRESET 6-50 - Thrombectomy Device
pRESET 6-50 - Thrombectomy Device
phenox today announced the introduction of the pRESET® 6-50 mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) stroke

Share this Post

phenox announces the expansion of their technology portfolio for acute ischemic stroke with the global launch of the pRESET® 6-50 mechanical thrombectomy device.

Adding to their already extensive technology portfolio, phenox today announced the introduction of the pRESET® 6-50 mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) stroke. This latest addition makes the pRESET 6-50 the longest stent retriever in the phenox portfolio and one of the longest stent retrievers available on the market for mechanical thrombectomy. Now offering a complete portfolio of 7 different sizes, phenox continues to demonstrate their ability to bring new devices to the market quickly in response to clinical evidence and market demands.

“Our physician customers strive for first pass effect when treating patients with acute LVO stroke as the evidence suggests it results in better patient outcomes. We are pleased to offer the new pRESET 6-50 as another tool in their stroke armamentarium, and further improving the chances of achieving better outcomes for their patients. - Hermann Monstadt, Managing Partner of phenox GmbH.

phenox will continue to innovate and introduce best-in-class new devices to the market that are based on physician input and data-driven evidence. Patients are at the forefront of innovation at phenox and devices are engineered with the objective of improving the lives and outcomes of stroke sufferers throughout the world.

“We look forward to delivering more novel devices to our physicians as we continue to expand and innovate as a company. pRESET 6-50 promises to be a great success in offering the potential of improved outcomes for stroke patients around the world.” Ralf Hannes, Managing Partner, Phenox GmbH.